SAP Cofounder Forms New Pharmaceutical Company
Dietmar Hopp, cofounder of the German information technology giant SAP AG (Waldorff, Germany) is forming a new pharmaceutical company from the merger of two German biopharmaceutical companies: Axaron Bioscience AG (Heidelberg, Germany) and Lion Bioscience AG (Heidelberg, Germany).
Dietmar Hopp, cofounder of the German information technology giant SAPAG (Waldorff, Germany, www.sap.com)is forming a new pharmaceutical company from the merger of two Germanbiopharmaceutical companies: Axaron Bioscience AG (Heidelberg, Germany,www.axaron.com) and Lion BioscienceAG (Heidelberg, Germany, www.lionbioscience.com).
"I see great potential in the area of life sciences and itsprofessional development," said Hopp, in commenting on the formation ofthe new company.
The new company will have funds of EUR 51 million ($64.5 million) ofwhich EUR 21 million ($26.5 million) will come from the Hopp family.The majority shareholder of Axaron Bioscience, the German chemicalgiant BASF AG (Ludwigshafen, Germany, www.basf.com) will invest EUR 7 million ($8.8million) in the new company. A further EUR 23 million ($29.0 million)will come from Lion Bioscience.
The new company will focus on drug development for central nervoussystem disease. Its lead candidate is "AX200," a product for treatingstrokes.
The name of the new company will be decided at Lion's annual meetingthis fall. It will be headed by two management board members: AlfredBach, now CEO of Axaron, and Peter Willinger, now CEO of LionBioscience.
Axaron Bioscience was founded in 1997 as a joint venture between BASFand Lynx Therapeutics (now Solexa, Hayward, CA, www.solexa.com) andbecame an independent company in 2001. Lion Bioscience was founded in1997 as a bioinformatics company and was restructured by new managementin 2004.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
